Chinese biotech company Vigonvita Life Sciences has filed for an initial public offering (IPO) on the Hong Kong Stock ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, raising $126 million for its pipeline of small-molecule cancer drugs.

The biotech is seeking funding for the programs from investors who have plenty of IPOs to pick from. Ab&B is one of eight biotechs that have filed to go public in Hong Kong over the past month and ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers.

Shenzhen-headquartered electric vehicle battery firm Contemporary Amperex Technology Co., Limited (CATL) has filed an ...

CATL is also listed on the Shenzhen stock exchange, boasting a market cap of $150.5 billion. The battery giant supplies big ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics revealing plans to go public while Hong Kong-listed Ascentage Pharma joins ...

Contemporary Amperex Technology Co. Ltd. has filed its application for a jumbo listing in Hong Kong that could be the city’s ...

China’s Contemporary Amperex Technology (CATL), the world’s largest producer of batteries for electric vehicles and a supplier for Tesla, has applied for a listing in Hong Kong, setting sights on one ...

Wealth management and family offices will be a major growth engine for Hong Kong, as many prominent clans in Asia have shown an interest in setting up entities to manage their fortunes ...

Takeda paid $100m upfront for the option to licence olverembatinib outside China, Hong Kong, Macau ... "Ascentage Pharma raises $126m in first biotech IPO of 2025" was originally created and ...

The company sold 7,325,000 American Depositary shares at $17.25 each. Shares for the company began trading today (24 January) ...